Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | PPIA | P62937 | 1/20 | 0.55 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.54 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.54 |
| ▸ | PTPRC | P08575 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | F2R | P25116 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28171047 | 0.87 | LMNA (0.50) | LMNAGAAPTGS1PPIAKCNK3 | |
| Hydrochloric Acid SCHEMBL8393906 | 0.85 | LMNA (0.60) | LMNAGAAPTGS1PPIAKCNK3 | |
| SCHEMBL7001833 | 0.84 | LMNA (0.68) | LMNAGAAPTGS1PPIAKCNK3 | |
| SCHEMBL27531979 | 0.82 | LMNA (0.66) | LMNAGAAPTGS1PPIAKCNK3 | |
| SCHEMBL1128084 | 0.81 | LMNA (0.70) | LMNAGAAPTGS1PPIAKCNK3 | |
| SCHEMBL9830646 | 0.81 | GAA (0.75) | LMNAGAAPTGS1PPIAKCNK3 | |
| SCHEMBL3964208 | 0.79 | LMNA (0.72) | LMNAGAAPTGS1PPIAKCNK3 | |
| SCHEMBL15200658 | 0.79 | LMNA (0.62) | LMNAGAAPTGS1PPIAKCNK3 | |
| SCHEMBL3418660 | 0.79 | LMNA (0.62) | LMNAGAAPTGS1PPIAKCNK3 | |
| SCHEMBL118007 | 0.79 | LMNA (0.60) | LMNAGAAPTGS1KCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872129-B2 | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| US-20090118278-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-07 | — | — | US | disclosed |
| US-7491730-B2 | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-17 | — | — | US | disclosed |
| CN-101037438-A | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMA (US) | 2007-09-19 | — | — | CN | disclosed |
| CN-1319968-C | Pyrazole compositions useful as inhibitors of GSK-3 | VERTEX PHARMA (US) | 2007-06-06 | — | — | CN | disclosed |
| EP-1739087-A1 | Pyrazole compositions useful as inhibitors of gsk-3 | Vertex Pharmaceuticals Incorporated (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1532145-B1 | PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMA (US) | 2006-09-13 | — | — | EP | disclosed |
| CN-1681815-A | Pyrazole compositions useful as inhibitors of GSK-3 | VERTEX PHARMA (US) | 2005-10-12 | — | — | CN | disclosed |
| EP-1532145-A1 | PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | Vertex Pharmaceuticals Incorporated (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040039007-A1 | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-26 | — | — | US | disclosed |
| WO-2004013140-A1 | PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-02-12 | — | — | WO | disclosed |
| US-5106843-A | Treatment of migraine, emesis, anxiety, gastrointestinal disorders, psychological disorders | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-04-21 | — | — | US | disclosed |
| EP-0323077-B1 | HETEROCYCLIC COMPOUNDS | JOHN WYETH & BROTHER LIMITED (GB) | 1991-09-11 | — | — | EP | disclosed |
| US-4983600-A | Antiemetics, antianxiety agents, gastrointestinal disorders | JOHN WYETH & BROTHER LIMITED (GB) | 1991-01-08 | — | — | US | disclosed |
| EP-0323077-A1 | Heterocyclic compounds | JOHN WYETH & BROTHER LIMITED (GB) | 1989-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118278-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | GSK3B, GSK3A, GSKIP | LMNA 1030/4885GAA 1226/4885PTGS1 2618/4885 |
| US-20040039007-A1 | Compositions useful as inhibitors of GSK-3 | GSK3A, GSK3B, GSKIP | LMNA 1062/4885GAA 1592/4885PTGS1 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.